Sidoti Csr Analysts Lower Earnings Estimates for USANA Health Sciences, Inc. (NYSE:USNA)

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti Csr reduced their Q2 2024 earnings estimates for USANA Health Sciences in a note issued to investors on Wednesday, May 1st. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings of $0.62 per share for the quarter, down from their prior forecast of $0.67. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.75 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2024 earnings at $0.64 EPS, Q4 2024 earnings at $0.68 EPS, FY2024 earnings at $2.80 EPS, Q1 2025 earnings at $0.86 EPS, Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.86 EPS and Q4 2025 earnings at $0.88 EPS.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The company had revenue of $221.08 million for the quarter, compared to analyst estimates of $206.70 million.

A number of other equities analysts have also issued reports on the stock. DA Davidson reduced their target price on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a research report on Thursday, February 22nd. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 12th.

USANA Health Sciences Trading Down 3.3 %

Shares of USNA stock opened at $45.55 on Thursday. USANA Health Sciences has a 1 year low of $41.45 and a 1 year high of $69.60. The firm’s 50 day moving average is $46.62 and its 200-day moving average is $48.36. The firm has a market capitalization of $876.38 million, a price-to-earnings ratio of 14.19, a PEG ratio of 1.38 and a beta of 0.94.

Institutional Investors Weigh In On USANA Health Sciences

Several large investors have recently made changes to their positions in the stock. CWM LLC increased its position in shares of USANA Health Sciences by 21.8% during the first quarter. CWM LLC now owns 1,543 shares of the company’s stock worth $75,000 after acquiring an additional 276 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in USANA Health Sciences by 1.2% during the fourth quarter. New York State Common Retirement Fund now owns 24,500 shares of the company’s stock worth $1,313,000 after purchasing an additional 279 shares during the last quarter. Swiss National Bank boosted its holdings in USANA Health Sciences by 1.2% during the third quarter. Swiss National Bank now owns 25,500 shares of the company’s stock worth $1,495,000 after purchasing an additional 300 shares during the last quarter. Rhumbline Advisers boosted its holdings in USANA Health Sciences by 1.4% during the third quarter. Rhumbline Advisers now owns 34,942 shares of the company’s stock worth $2,048,000 after purchasing an additional 496 shares during the last quarter. Finally, Strs Ohio boosted its holdings in USANA Health Sciences by 4.8% during the third quarter. Strs Ohio now owns 10,900 shares of the company’s stock worth $638,000 after purchasing an additional 500 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling

In other USANA Health Sciences news, COO Walter Noot sold 5,240 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $49.05, for a total value of $257,022.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other USANA Health Sciences news, COO Walter Noot sold 5,240 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $49.05, for a total value of $257,022.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Kevin Guest sold 11,011 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.00, for a total transaction of $539,539.00. Following the completion of the sale, the chairman now directly owns 10,491 shares of the company’s stock, valued at approximately $514,059. The disclosure for this sale can be found here. Insiders sold a total of 28,598 shares of company stock valued at $1,379,499 over the last ninety days. Insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.